Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
Inder Kaul, Sharon Sawchak, Amy Claxton, Colin Sauder, Howard H Hassman, Rishi Kakar, David P Walling, Leslie Citrome, Haiyuan Zhu, Andrew C Miller, Stephen K Brannan · 2024
Read Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials by Inder Kaul, Sharon Sawchak, Amy Claxton, Colin Sauder, Howard H Hassman, Rishi Kakar, David P Walling, Leslie Citrome, Haiyuan Zhu, Andrew C Miller, Stephen K Brannan (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11531488.txt.
Description
In the 5-week, randomized, double-blind, placebo-controlled EMERGENT-1 (NCT03697252), EMERGENT-2 (NCT04659161), and EMERGENT-3 (NCT04738123) trials, xanomeline and trospium chloride (formerly known as KarXT) significantly improved symptoms of schizophrenia and was generally well tolerated. We pooled data from the EMERGENT trials to further characterize the efficacy of xanomeline/trospium and provide sufficient statistical power to analyze responses in participant subgroups.
Catalog record
| CREATOR | Inder Kaul, Sharon Sawchak, Amy Claxton, Colin Sauder, Howard H Hassman, Rishi Kakar, David P Walling, Leslie Citrome, Haiyuan Zhu, Andrew C Miller, Stephen K Brannan |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |